# Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain

> **NCT00452777** · PHASE2 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 193 (actual)

## Conditions studied

- Diabetic Neuropathic Pain

## Interventions

- **DRUG:** BVT.115959
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00452777
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2007-12
- **Final completion:** 2008-01
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2014-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452777, "Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00452777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*